#7cbde1_Small_Sep-Oct 2024 DRA Journal Cover

The latest DRA Journal issue showcases Asia's dental innovation, featuring Thailand's pioneering stem cell research, advanced clinical techniques like 3D-printed dentures for senior patients and digital workflows for implant restorations, a review of top Asian dental startups, and strategies for improving dental practice culture.

>> FlipBook Version (Available in English)

>> Mobile-Friendly Version (Available in Multiple Languages)

Click here to access Asia's first Open-Access, Multi-Language Dental Publication

Q&M Dental Group Announces Major Operational Changes

Laboratory Operations Suspended as COVID Testing Demand Wanes

Q&M Dental Group has made the strategic decision to suspend operations at its Acumen laboratory facility, following the expiration of its laboratory licence on September 15th. This significant move comes in response to sustained financial challenges, with Acumen experiencing continuous losses throughout 2023 and into the first half of 2024, primarily attributed to diminishing demand for COVID-19 PCR testing services.

Strategic Reallocation of Resources

The dental healthcare provider has indicated plans to strategically redirect resources from these operations. The group intends to channel potential cost savings towards the development of new diagnostics-related ventures within Acumen’s existing portfolio, demonstrating a forward-looking approach to evolving market conditions.

Closure of Sengkang Testing and Vaccination Centre

In a related development, the company has announced the forthcoming closure of its joint testing and vaccination centre in Sengkang. This closure, scheduled for 1 December, comes in accordance with directives from the Ministry of Health (MOH), marking the end of another chapter in Singapore’s COVID-19 response infrastructure.

Future Outlook and Business Continuity

While the suspension of Acumen’s testing operations will impact the group’s revenue stream, Q&M has maintained an optimistic outlook for future opportunities. The company has expressed its intention to actively pursue new MOH contract opportunities, leaving the door open for potential re-entry into clinical testing services. The group has specifically indicated its willingness to consider reapplying for a laboratory licence in the future, suggesting a flexible approach to market conditions and regulatory requirements.

The restructuring represents a significant pivot in Q&M’s operational strategy, reflecting broader changes in Singapore’s healthcare landscape as the country continues to adapt to post-pandemic healthcare needs.

The information and viewpoints presented in the above news piece or article do not necessarily reflect the official stance or policy of Dental Resource Asia or the DRA Journal. While we strive to ensure the accuracy of our content, Dental Resource Asia (DRA) or DRA Journal cannot guarantee the constant correctness, comprehensiveness, or timeliness of all the information contained within this website or journal.

Please be aware that all product details, product specifications, and data on this website or journal may be modified without prior notice in order to enhance reliability, functionality, design, or for other reasons.

The content contributed by our bloggers or authors represents their personal opinions and is not intended to defame or discredit any religion, ethnic group, club, organisation, company, individual, or any entity or individual.

Leave a Reply

Your email address will not be published. Required fields are marked *